Labcorp Plasma Complete Real-World Evidence (RWE) Analysis to Demonstrate Clinical Utility and Actionability in Cancer Patients

Comprehensive genomic profiling via next-generation sequencing (NGS) can help inform cancer treatment decisions based on the presence of clinically relevant biomarkers. Although still early in its clinical adoption, liquid biopsy testing is a complementary approach for tumor genomic profiling when tissue is limited, exhausted, unavailable, or molecular results are pending. Labcorp Plasma Complete^TM is a molecular genomic liquid biopsy NGS test that analyzes cell free DNA (cfDNA) derived from plasma to identify genomic alterations in patients with advanced or metastatic solid tumors. Clinical actionability of detected alterations is evaluated as part of the testing workflow to help determine eligibility for approved therapies, targeted treatment options, clinical guideline alignment, and clinical trial matching. Since the commercial launch of the Labcorp Plasma Complete laboratory developed test (LDT) in February 2025, over 750 cases have been reported to help guide clinical decision-making for ordering providers